

GTGAGAGARGRGG (SEQ ID NO:17), SGGRGRGG (SEQ ID NO:18), RGGSGGRRGRGR
(SEQ ID NO:19), RARGRGRGRGEKRPRS (SEQ ID NO:20), SSSSGSPRRPPPGR (SEQ ID
NO:21), RPPPGRRPFFHPVGEADYFEYHQEG (SEQ ID NO:22), PDVPPGAI (SEQ ID
NO:23), PGAIEQGPA (SEQ ID NO:24), GPSTGPRG (SEQ ID NO:25), GQGDGGRRK (SEQ
ID NO:26), DGGRRKKGGWFGKHR (SEQ ID NO:27), GKHRGQGGSN (SEQ ID NO:28),
GQGGSNPK (SEQ ID NO:29), NPKFENIA (SEQ ID NO:30), RSHVERTT (SEQ ID NO:31),
VFVYGGSKT (SEQ ID NO:32), GSKTSLYNL (SEQ ID NO:33), GMAPGPGP (SEQ ID
NO:34), PQGPLRE (SEQ ID NO:35), CNIRVTVC (SEQ ID NO:36), RVTVC SFDDG (SEQ
ID NO:37), PPWFPPMVEG (SEQ ID NO:38) and combinations thereof or portions thereof
sufficient to react with autoantibody, wherein the peptide [comprises up to about forty amino
acids and] is present either in free form or bound to a carrier molecule.

28. (three times amended) A method comprising administering to a individual a peptide
composition comprising a peptide molecule consisting of about forty amino acids or less and
comprising a peptide sequence selected from the group consisting of PPPGRRP (SEQ ID NO:1),
GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3),
GAGAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7),
GPQRRGGDNHGRGRGRGRGRGGGRPG (SEQ ID NO:13), GGSGSGPRHRDGVRRPQKRP
(SEQ ID NO:14), RPQKRPS (SEQ ID NO:15), QKRPSIGCKGTHGGTG (SEQ ID NO:16),
GTGAGAGARGRGG (SEQ ID NO:17), SGGRGRGG (SEQ ID NO:18), RGGSGGRRGRGR
(SEQ ID NO:19), RARGRGRGRGEKRPRS (SEQ ID NO:20), SSSSGSPRRPPPGR (SEQ ID

H1
cont

NO:21), RPPPGRRPFFHPVGEADYFEYHQEG (SEQ ID NO:22), PDVPPGAI (SEQ ID NO:23), PGAIEQGPA (SEQ ID NO:24), GPSTGPRG (SEQ ID NO:25), GQGDGGRRK (SEQ ID NO:26), , GKHRGQGGSN (SEQ ID NO:28), GQGGSNPK (SEQ ID NO:29), NPKFENIA (SEQ ID NO:30), RSHVERTT (SEQ ID NO:31), VFVYGGSKT (SEQ ID NO:32), GSKTSLYNL (SEQ ID NO:33), GMAPGPGP (SEQ ID NO:34), PQGPLRE (SEQ ID NO:35), CNIRVTVC (SEQ ID NO:36), RVTVCSEDDG (SEQ ID NO:37), PPWFPPMVEG (SEQ ID NO:38), and combinations or [immunogenic] portions thereof sufficient to react with autoantibody, wherein the peptide [comprises up to about forty amino acids and]is present either in free form or bound to a carrier molecule, and wherein the composition is in a pharmaceutically acceptable carrier for administration of the composition in an amount and mode of administration effective to induce tolerance to EBV-associated immune responses.

H2

35. (twice amended) A method for determining the likelihood that an individual has or will develop an autoimmune disorder comprising screening their antibodies for reactivity with a peptide molecule consisting of about forty amino acids or less and comprising a peptide sequence selected from the group consisting of PPPGRRP (SEQ ID NO:1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3), GAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7), GPQRRGGDNHGRGRGRGRGRGGGRPG (SEQ ID NO:13), GGSGSGPRHRDGVRRPQKRP (SEQ ID NO:14), RPQKRPS (SEQ ID NO:15), QKRPSIGCKGTHGGTG (SEQ ID NO:16), GTGAGAGARGRGG (SEQ ID NO:17), SGGRGRGG (SEQ ID NO:18), RGGSGGRRGRGR (SEQ ID NO:19),